<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919542</url>
  </required_header>
  <id_info>
    <org_study_id>ITCRBY24-ENLA</org_study_id>
    <nct_id>NCT00919542</nct_id>
  </id_info>
  <brief_title>Ciclosporin in the Management of New Erythema Nodosum Leprosum</brief_title>
  <official_title>A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Homes and Hospitals of St Giles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alert Hospital, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 2A: Ciclosporin in the management of new Erythema Nodosum Leprosum

      Objective: A pilot (double blind controlled) study randomizing patients to treatment either
      with Ciclosporin or Prednisolone to assess the safety, tolerability and efficacy of
      Ciclosporin in the treatment of patients with new acute Type 2 reactions (ENL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot (double blind controlled) study randomizing patients to treatment either with
      Ciclosporin or Prednisolone to assess the safety, tolerability and efficacy of Ciclosporin in
      the treatment of patients with new acute Type 2 reactions (ENL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ENL recurrence episodes per patient</measure>
    <time_frame>up to 32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time to ENL recurrence after initial control</measure>
    <time_frame>up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of additional prednisolone required by patients</measure>
    <time_frame>up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events for patients in each treatment arm</measure>
    <time_frame>up to 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in score in Quality of Life assessment between start and end for patients in each treatment arm</measure>
    <time_frame>up to 32 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Leprosy</condition>
  <arm_group>
    <arm_group_label>prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard course of prednisolone given in a reducing regimen over 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <description>Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)</description>
    <arm_group_label>Ciclosporin</arm_group_label>
    <other_name>cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>prednisolone 40mg daily then reducing regimen over 16 weeks</description>
    <arm_group_label>prednisolone</arm_group_label>
    <other_name>corticosteroids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with clinical evidence of new ENL

          -  Aged 18-65

          -  Weigh more than 30Kg

        Exclusion Criteria:

          -  Unwillingness to give informed consent

          -  Patients with severe active infections such as tuberculosis

          -  Pregnant or breastfeeding women (see Appendix II)

          -  Those with renal failure, abnormal renal function, hypertensive

          -  Patients taking thalidomide currently or within the last 3 months

          -  Patients not willing to return for follow-up

          -  Women of reproductive age not willing to use contraception for the duration of the
             study ( see Appendix II)

          -  HIV positive patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana NJ Lockwood, MBchB</last_name>
    <role>Study Director</role>
    <affiliation>London SHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alert Hospital</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>March 21, 2015</last_update_submitted>
  <last_update_submitted_qc>March 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London School of Hygiene and Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Saba Lambert</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Leprosy</keyword>
  <keyword>ENL</keyword>
  <keyword>Erythema Nodosum Leprosum</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Ciclosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leprosy</mesh_term>
    <mesh_term>Erythema Nodosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

